Work

AML-867: Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016–2026)

Year: 2026

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(26)01862-8

Authors: Arashdeep Singh, Sidharth Mahajan, Madho Mal, Shankar Biswas, Bhawarpreet Bhatti, Gurmanleen Sohi, Karanbir Purewal, Aniroodh Venugopalan, Shravani Katkam

Institutions: Allegheny General Hospital, MacNeal Hospital, Marshall University, Ivano-Frankivsk National Medical University, Government Medical College, Amritsar, Government Medical College, Dr. B.R. Ambedkar State Institute of Medical Sciences, Rajarajeswari Medical College and Hospital, Kurnool Medical College

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7204708024

Cites:

Cited by:

Related to: